Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy

International Journal of Radiation Oncology Biology Physics

Volumn 87, Issue 5, 2013, Pages 983-991

  Bazan, Jose G ^a   Luxton, Gary ^a   Kozak, Margaret M ^a   Anderson, Eric M ^a   Hancock, Steven L ^a   Kapp, Daniel S ^a   Kidd, Elizabeth A ^a   Koong, Albert C ^a   Chang, Daniel T ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONCURRENT CHEMOTHERAPY; DOSIMETRIC PARAMETER; HEMATOLOGIC TOXICITY; INTENSITY MODULATED RADIATION THERAPY; LOGISTIC REGRESSIONS; METHODS AND MATERIALS; NORMAL TISSUE COMPLICATION PROBABILITIES; NORMAL-TISSUE COMPLICATION PROBABILITY MODELS;

BONE; CHEMOTHERAPY; CONSTRAINED OPTIMIZATION; DOSIMETRY; PATIENT MONITORING; PROBABILITY; RADIOTHERAPY; TISSUE; TOXICITY;

PHYSICAL THERAPY;

BICALUTAMIDE; CAPECITABINE; CARBOPLATIN; CISPLATIN; FLUOROURACIL; LEUPRORELIN; MITOMYCIN; ANTINEOPLASTIC AGENT;

ADULT; ANUS CANCER; AREA UNDER THE CURVE; BONE MARROW; CHEMORADIOTHERAPY; CONFERENCE PAPER; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; ILIAC BONE; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; LUMBOSACRAL SPINE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PELVIC GIRDLE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RECTUM CANCER; THROMBOCYTOPENIA; AGED; ANUS NEOPLASMS; BACK; DRUG ADMINISTRATION; DRUG EFFECTS; GENITAL NEOPLASMS, FEMALE; MIDDLE AGED; PELVIS; PROBABILITY; PROSTATIC NEOPLASMS; RADIATION RESPONSE; RADIOGRAPHY; RADIOTHERAPY; RECTAL NEOPLASMS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; STATISTICAL MODEL;

AGED; ANTINEOPLASTIC AGENTS; ANUS NEOPLASMS; BONE MARROW; CHEMORADIOTHERAPY; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; GENITAL NEOPLASMS, FEMALE; HUMANS; ILIUM; LEUKOPENIA; LOGISTIC MODELS; LUMBOSACRAL REGION; LYMPHATIC IRRADIATION; MALE; MIDDLE AGED; MITOMYCIN; NEUTROPENIA; PELVIC BONES; PELVIS; PROBABILITY; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RECTAL NEOPLASMS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 84888289649     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.09.017     Document Type: Conference Paper

References (15)

1. K. Albuquerque, D. Giangreco, and C. Morrison Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT Int J Radiat Oncol Biol Phys 79 2011 1043 1047
2. L.K. Mell, J.D. Kochanski, and J.C. Roeske Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy Int J Radiat Oncol Biol Phys 66 2006 1356 1365
3. B.S. Rose, B. Aydogan, and Y. Liang Normal Tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy Int J Radiat Oncol Biol Phys 79 2011 800 807
4. L.K. Mell, D.A. Schomas, and J.K. Salama Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy Int J Radiat Oncol Biol Phys 70 2008 1431 1437
5. J.G. Bazan, G. Luxton, and E.C. Mok Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal Int J Radiat Oncol Biol Phys 84 2012 700 706
6. R.D. James, R. Glynne-Jones, and H.M. Meadows Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): A randomised, phase 3, open-label, 2×2 factorial trial Lancet Oncol 14 2013 516 524
7. G. Luxton, P.J. Keall, and C.R. King A new formula for normal tissue complication probability (NTCP) as a function of equivalent uniform dose (EUD) Phys Med Biol 53 2008 23 36
8. A. Eisbruch, and R.K. Ten Haken Reply to Dr. Deasy Int J Radiat Oncol Biol Phys 47 2000 1459 1460
9. A.H. Klopp, J. Moughan, and L. Portelance Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer Int J Radiat Oncol Biol Phys 86 2013 83 90
10. B.S. Rose, Y. Liang, and S.K. Lau Correlation between radiation dose to (1)(8)F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy Int J Radiat Oncol Biol Phys 83 2012 1185 1191
11. Y. Liang, K. Messer, and B.S. Rose Impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer: principal component analysis on high dimensional data Int J Radiat Oncol Biol Phys 78 2010 912 919
12. J. Wang, B. Myles, and C. Wei Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma Dis Esophagus 2013 Apr 26 [epub ahead of print]. doi: 10.1111/dote.12074
13. J.A. Meyerhardt, P.J. Catalano, and D.G. Haller Influence of Body Mass Index on Outcomes and Treatment-Related Toxicity in Patients with Colon Carcinoma Cancer 98 2003 484 495
14. J.J. Griggs, M.E. Sorbero, and G.H. Lyman Undertreatment of obese women receiving breast cancer chemotherapy Arch Intern Med 165 2005 1267 1273
15. L.K. Mell Intensity modulated radiation therapy for gynecologic malignancies: a testable hypothesis Int J Radiat Oncol Biol Phys 84 2012 566 568